Hikma launches estradiol valerate injection
Estradiol valerate injection had a market value of roughly $16 million in the 12 months ending March 2021, according to IQVIA.
Hikma is introducing estradiol valerate injection in dosage strengths of 10 mg/ml, 20 mg/ml and 40 mg/ml.
The product is indicated in the treatment of vasomotor symptoms associated with menopause; in the management of hormonal imbalances due to castration or primary ovarian failure; and in the treatment of androgen-dependent carcinoma of the prostate.
Estradiol valerate injection had a market value of approximately $16 million in the 12 months ending March 2021, according to IQVIA.